<DOC>
	<DOCNO>NCT00427804</DOCNO>
	<brief_summary>This study pilot study determine whether patient TNFα excess decrease calcium absorption response calcitriol ( 1,25-dihydroxyvitamin D , active form vitamin D ) compare normal control . This initial pilot study do determine feasible conduct study TNFα could block ( e.g. , anti-TNFα therapy Enbrel® Remicade® ) improve vitamin D dependant calcium absorption thus bone health .</brief_summary>
	<brief_title>Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption</brief_title>
	<detailed_description>Vitamin D important maintenance normal calcium homeostasis improve efficacy calcium absorption small intestine . The efficacy calcium absorption decrease age , menopause , inflammatory state . Subjects low intestinal absorption calcium risk develop osteoporosis fracture . Early data suggest patient rheumatoid arthritis ( RA ) Crohn 's disease appear decrease calcium absorption . Patients RA Crohn 's disease elevate level TNFα local tissue systemically may cause resistance vitamin D dependant calcium absorption . Recently new vitamin D dependant calcium channel important calcium absorption discover small intestine call Transient Receptor Potential Vallinoid type 6 ( TRPV6 ) . We pre-clinical data rat suggest TNFα role inhibit expression protein decrease induction protein response vitamin D treatment . HYPOTHESIS : Subjects disease condition result elevate TNFα vitamin D resistance inability increase calcium absorption increase concentration calcitriol . STUDY DESIGN : Subjects : The study conduct Emory GCRC/Emory Clinic VA clinical research center . Study participant recruit Atlanta Veterans Administration Medical Center ( VAMC ) Emory Clinics participation study accord follow inclusion exclusion criterion Inclusion : Males , age 18 50 , history Crohn 's disease Rheumatoid Arthritis ( case ) healthy individual ( control ) Exclusion : Subjects already take activate vitamin D medication calcitriol , Zemplar® , Hectoral® , vitamin D deficiency define 25 ( OH ) D ≤ 20 ng/ml , post-menopausal woman ( absence menses great 6 month history FSH level &gt; 20 ) , history nephrolithiasis , history hypercalcemia hypercalciuria , short bowel disease , glucocorticoid use , use osteoporosis medication ( bisphosphonate , calcitonin teriparatide ) , chronic kidney disease ( calculate GFR &lt; 60 ml/min/1.73 m2 ) , history hyperparathyroidism ( PTH great upper limit normal ) hypoparathyroidism ( PTH low limit normal ) Procedures : Screening Phase : Case subject identify Rheumatology Gastroenterology clinic VA Emory Clinic . The subject 's doctor give patient brochure study study investigator 's name phone number contact . There also advertisements Rheumatology Gastroenterology clinic recruit subject study . Control subject identify posting VA hospital Emory Clinic designate area research posting . The subject initiate contact study personnel call number advertisement brochure . The study investigator pre-screen subject phone see subject eligible entry study . If subject remain eligible , subject invite VA clinical research center Emory GCRC/Emory Clinic inform consent . Screening Visit : The study investigator review inclusion exclusion criterion subject . If subject agree participate study , subject sign inform consent undergo baseline laboratory investigation total calcium , parathyroid hormone ( PTH ) , 25-hydroxyvitamin D , comprehensive panel include renal function , 24-hour urine collection calcium creatinine clearance . Subjects counseled take 600 mg calcium daily 400 IU day vitamin D. The subject instruct complete three day food diary future visit . They give schedule return follow visit . Visit # 1 ( baseline fractional absorption calcium ( FCA ) ) Subjects return clinical research center fast state baseline FCA test ( see specific method follow section ) . Subjects return three day food diary record . Subjects also blood drawn comprehensive panel include calcium renal function , 1,25-dihydroxyvitamin D , PTH level serum TNFα . The subject give calcitriol 0.25 mcg PO BID take 7 day . Visit # 2 ( FCA low dose calcitrol , 0.25 mcg PO BID ) Subjects take morning dose calcitriol 8 day visit # 2 . Subjects come clinic fasting state . They return 3 day food diary record . A repeat FCA perform . Subjects also blood drawn comprehensive panel include calcium renal function , 1,25-dihydroxyvitamin D , PTH level serum TNFα . After test complete , subject give calcitriol 0.50 mcg PO BID take 7 day . They schedule return clinical research center within 20 day minimum 7 day washout period . Visit # 3 ( FCA high dose calcitriol , 0.50 mcg PO BID ) Subjects take morning dose calcitriol 8 day visit # 3 . Subjects come clinic fasting state . They return 3 day food diary record . A repeat FCA perform . Subjects also blood drawn comprehensive panel include calcium renal function , 1,25-dihydroxyvitamin D , PTH level serum TNFα . Fractional absorption calcium ( FCA ) procedure Subjects come clinic overnight fast . After void fast urine , 24 hour urine collection begin . Each subject receive standard breakfast ( see FCA diet section ) contain approximately 211 mg calcium 45 IU vitamin D. Oral 43Ca administer patient drunk milk . 1.9 ml drawn sterile 43Ca ( calcium chloride ) vial syringe inject 4 ounce distilled water . The subject drink glass water . The glass rinse twice 4 ounce distilled water subject drink rinse . 2.7 ml 42Ca drawn sterile 42Ca ( calcium chloride ) vial sterile hypodermic syringe . The solution inject patient intravenously IV catheter flush 5 ml normal saline . The intravenous calcium infuse within 30 minute ingestion oral calcium . The subject discharge clinical research center continue 24 hour urine collection . The following morning , subject return 24 hour urine collection research clinic . The subject advise eat least 4 hour breakfast meal .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>Males Age 18 50 History Crohn 's disease Rheumatoid Arthritis ( case ) healthy individual ( control ) Subjects already take activate vitamin D medication calcitriol , Zemplar® , Hectoral® Vitamin D deficiency define 25 ( OH ) D ≤ 20 ng/ml Postmenopausal woman ( absence menses great 6 month history FSH level &gt; 20 ) History nephrolithiasis History hypercalcemia hypercalciuria Short bowel disease Glucocorticoid use Use osteoporosis medication ( bisphosphonate , calcitonin teriparatide ) Chronic kidney disease ( calculate GFR &lt; 60 ml/min/1.73 m2 ) History hyperparathyroidism ( PTH great upper limit normal ) Hypoparathyroidism ( PTH low limit normal )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Calcium absorption</keyword>
	<keyword>Vitamin D</keyword>
</DOC>